Выбор темы
Выбор стиля шрифта
Merck & Co новости
07/06
💡
МНЕНИЕ: Суд вряд ли удовлетворит иск Merck & Co, оспаривающий планы властей - Синара
07/07
💡
МНЕНИЕ: Очередная покупка Merck с высокой оценкой - Синара
06/05
💡
МНЕНИЕ: Акции Merck выросли до справедливого уровня - Синара
03/02
🔗
Seeking Alpha: Merck & Co., Inc. (MRK) CEO Rob Davis on Q4 2021 Results - Earnings Call Transcript
03/02
🔗
Invezz: Merck CEO on Q4 results: ‘all of our growth drivers are delivering'
03/02
🔗
Zacks Investment Research: Merck (MRK) Q4 Earnings and Revenues Beat Estimates
03/02
🔗
CNBC: Merck expects to sell $5 billion to $6 billion of its new Covid treatment pill in 2022
03/02
🔗
Benzinga: Merck Clocked $950M Sales In Q4 From COVID-19 Treatment, Issues FY22 Sales
03/02
🔗
CNBC Television: Merck earnings beat estimates, forecasts lower Covid pill sales
03/02
🔗
CNBC Television: Merck on track to deliver 3.1 million Covid pill courses to U.S. soon, CEO says
03/02
🔗
The Motley Fool: Merck Coughs Up a Failure With Its "Pipeline in a Product"
03/02
🔗
Market Watch: Merck tops Q4 estimates as COVID antiviral chalks up $952 million of sales
03/02
🔗
Reuters: Merck sees 2022 sales up nearly 20%, mostly on molnupiravir
02/02
🔗
Forbes: Will Merck Stock Rise After Its Q4 Results?
01/02
🔗
Zacks Investment Research: Will Merck (MRK) Succeed in Beating Q4 Earnings Expectations?
29/01
🔗
Seeking Alpha: Wide-Moat Stocks On Sale - The February 2022 Heat Map
28/01
🔗
Zacks Investment Research: Merck (MRK) Keytruda Gets EU Nod for Expanded Kidney Cancer Use
28/01
🔗
Benzinga: Merck's COVID-19 Pill works Against Omicron, Lab Studies Show
28/01
🔗
Market Watch: Merck, Ridgeback says COVID-19 pill molnupiravir shows antiviral activity against omicron variant
25/01
🔗
Zacks Investment Research: Merck's (MRK) Chronic Cough Drug Gets CRL From FDA
25/01
🔗
Proactive Investors: Britain needs 6,000 more volunteers to take Merck's COVID-19 pill mainstream
24/01
🔗
Benzinga: Britain To Test Merck - Ridgeback Biotherapeutics' COVID-19 Antiviral Pill In Hospitalized Patients
24/01
🔗
Pulse2: Merck (MRK): FDA Requests More Information About Gefapixant
24/01
🔗
Benzinga: Merck's Gefapixant For Chronic Cough Slapped With FDA Complete Response Letter
21/01
🔗
Benzinga: Merck Scores Win In Insurance Battle Over Cyberattack - Bloomberg Report
18/01
🔗
CNBC Television: Final Trades: Wynn, Goldman Sachs, Merck & more
18/01
🔗
Market Watch: Merck and Ridgeback Biotherapeutics to supply 3 million doses of COVID antiviral to Unicef in 2022
14/01
🔗
The Motley Fool: Merck Snags Yet Another Indication for This Drug Combo
13/01
🔗
Seeking Alpha: Adding Merck To My High Quality Pharma Holdings
13/01
🔗
Zacks Investment Research: IMV Doses First Patient in the Mid-Stage Study With Keytruda
12/01
💡
МНЕНИЕ: 2022 год может сложиться удачно для Merck & Co - Финам
11/01
🔗
Seeking Alpha: Merck & Co., Inc. (MRK) CEO Rob Davis Presents at 40th Annual J.P. Morgan Healthcare Conference (Transcript)
10/01
🔗
Zacks Investment Research: Absci (ABSI) Inks Research Agreement With Merck, Stock Up
08/01
🔗
Business Wire: Merck to Hold Fourth-Quarter and Full-Year 2021 Sales and Earnings Conference Call on February 3
07/01
🔗
Invezz: Absci Corp up 50% after announcing research collaboration with Merck
07/01
🔗
InvestorPlace: ABSI Stock: 7 Things for Investors to Know About the Merck Deal That Has Absci Shares Flying Today
07/01
🔗
Market Watch: Absci stock rockets after collaboration with Merck could lead to more than $600 million in payments
05/01
🔗
Zacks Investment Research: 5 Small-Cap ETFs to Profit From the January Effect
05/01
🔗
Business Wire: Merck to Present at the 40th Annual J.P. Morgan Healthcare Conference
04/01
🔗
Seeking Alpha: Merck & Co.: Attractive Valuation With Margin Stability In Focus
03/01
🔗
Seeking Alpha: Dogs Of The Dow Performance Does Not Keep Pace In 2021
01/01
🔗
The Motley Fool: These 3 Stocks Just Hiked Their Dividends: Should You Buy Them?
29/12
📉
Падение акций Moderna достигло 50% от исторического максимума
24/12
🔗
Zacks Investment Research: Merck's (MRK) COVID Pill Gets FDA Nod for Emergency Use
24/12
🔗
Proactive Investors: Merck's COVID-19 pill authorised for emergency use by US FDA
24/12
🔗
CNBC Television: Covid patients now have an option, says Merck exec
23/12
🔗
TechCrunch: Merck's COVID-19 antiviral pill is the second authorized by the FDA
23/12
🔗
Forbes: FDA Approves Merck's Antiviral Pill For Emergency Use
23/12
🔗
Market Watch: FDA authorizes Merck's COVID-19 antiviral but only when other treatments are 'not accessible' or 'appropriate'
23/12
🔗
Benzinga: FDA Approves Another COVID-19 Antiviral Pill, This Time From Merck
22/12
🔗
Forbes: France Cancels Order For Merck's Anti-Covid Pill After Disappointing Trial Results
22/12
🔗
Benzinga: FDA To Possibly Authorize Pfizer, Merck COVID-19 Antiviral Pills This Week: Bloomberg
17/12
🔗
Wall Street Journal: Exclusive Look: Merck Teams Up With Rival J&J to Help Produce Its Covid Vaccine | WSJ
17/12
🔗
The Motley Fool: Why This Once-Promising HIV Candidate Could Be in Trouble
16/12
🔗
Zacks Investment Research: Merck's (MRK) Pneumococcal Vaccine Vaxneuvance Gets EU Nod
14/12
🔗
Zacks Investment Research: Merck's (MRK) HIV Studies on Islatravir Put on Clinical Hold
14/12
🔗
Reuters: German chip chemical supplier Merck to invest 500 million euros in Taiwan
14/12
🔗
Seeking Alpha: BELLUS Proof Of Data In Chronic Cough Using BLU-5937 Brings Hope To Patients
13/12
🔗
Benzinga: Merck Raises $1 Billion Via Inaugural Sustainability Bond
12/12
🔗
Pulse2: Merck Stock (MRK): $90 Price Target From Wells Fargo
08/12
🔗
Zacks Investment Research: Remedies for Omicron Apparent, Markets Up Again
08/12
🔗
Market Watch: Merck invests nearly $700 million in M Ventures to seed young companies
08/12
🔗
Invezz: Should you buy Palantir stock after partnering with Merck to tackle chip shortage?
07/12
🔗
Forbes: Merck Enters Oversold Territory
07/12
🔗
Barrons: Merck Stock Sinks as Analyst Sees It Going Nowhere Fast
07/12
🔗
Barrons: Merck Stock Sinks as Analyst Sees It Going Nowhere Fast
07/12
🔗
Benzinga: Merck Stops Enrollment In Two Islatravir Trials For Prevention Of HIV Infection
06/12
🔗
Zacks Investment Research: Merck's (MRK) Keytruda Gets FDA Nod for Expanded Melanoma Use
06/12
🔗
Benzinga: Canada, Merck Ink Supply Pact For 1M Doses Of Molnupiravir For COVID-19
06/12
🔗
Benzinga: Merck's Keytruda Wins Eighth FDA Approval Of 2021, This Time For Adjuvant, Pediatric Melanoma Settings
04/12
🔗
Seeking Alpha: 2 Rich Dividends To Buy Before The Santa Claus Rally
03/12
🔗
Seeking Alpha: Early Stage COVID Treatments: Merck's Molnupiravir Struggles
02/12
🔗
GuruFocus: Merck, Novartis in Line for Key FDA Approvals This Month
02/12
🔗
Zacks Investment Research: Merck (MRK) Vaxneuvance sBLA for Pediatrics Gets Priority Review
01/12
🔗
Seeking Alpha: Merck & Co., Inc. (MRK) Management on 4th Annual Evercore ISI HealthCONx Virtual Conference (Transcript)
01/12
🔗
Forbes: What's Next For Merck Stock After FDA Advisors Back Its Covid-19 Pill?
01/12
🔗
Zacks Investment Research: Merck (MRK) Up as COVID Pill Gets FDA Panel's Positive Vote
01/12
🔗
Zacks Investment Research: AstraZeneca, Merck's Lynparza sNDA Gets FDA Priority Tag
01/12
🔗
Market Watch: After high hopes for Merck's COVID-19 pill, Wall Street now expects a ‘tepid' authorization
01/12
🔗
Benzinga: Merck's Pneumococcal 15-valent Conjugate Vaccine Under Priority FDA Review For Use In Kids
01/12
🔗
Proactive Investors: Merck's new Covid pill gets the US regulatory green light - but only just
01/12
FDA советует таблетку от Merck для экстренного использования
01/12
🔗
Seeking Alpha: Merck Is A Buy Now
01/12
🔗
Seeking Alpha: Bargain Alert: Merck Is A Strong Buy On The Drop
01/12
🔗
CNBC Television: FDA panel recommends Merck Covid pill for emergency use
01/12
🔗
CNET: FDA panel narrowly moves to authorize Merck's COVID treatment pill
01/12
🔗
Business Insider: An FDA expert panel narrowly supports the first COVID-19 pill but suggests restrictions on its use driven by safety concerns
30/11
🔗
Invezz: Is Merck stock a buy or sell as covid pill efficacy concerns send shares crushing?
30/11
🔗
Zacks Investment Research: Merck's (MRK) Keytruda Gets Europe Nod for Two Carcinomas
30/11
🔗
Forbes: Is A Rise Imminent For Merck Stock After An 8% Fall In A Month?
30/11
🔗
Market Watch: Merck, AstraZeneca's sNDA for breast cancer treatment granted priority review by the FDA
29/11
🔗
Benzinga: FDA's AdComm Meet Tomorrow To Review Safety, Efficacy of Merck's COVID-19 Pill
29/11
🔗
Market Watch: The Ratings Game: Merck stock dives after Citi downgrades on ‘high probability' that HIV treatment will be abandoned
29/11
🔗
GuruFocus: So Far, Joe Biden Leads All Presidents in Market Performance
29/11
🔗
Benzinga: Europe Approves Merck-Eisai's Keytruda/Lenvima Combo Therapy For Endometrial Carcinoma
29/11
🔗
24/7 Wall Street: 5 Buy-Rated Blue Chip Stocks With Dividends Expected to Rise This Week
29/11
🔗
Zacks Investment Research: Merck (MRK) COVID Pill Less Effective in Final Study, Stock Down
28/11
🔗
The Motley Fool: Who Would Be the Best FDA Commissioner for Biotech Investors?
26/11
🔗
Proactive Investors: Merck's COVID drug not as effective as first thought
26/11
🔗
Schaeffers Research: Blue-Chip Drugmaker Falls on Newest Covid Treatment Data
Загрузить еще